On November 24, 2025, Novo Nordisk announced top-line results from its phase 3 evoke and evoke+ trials, revealing that oral semaglutide did not show superiority over placebo in slowing progression of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback